克唑替尼治疗ROS1重排晚期非小细胞肺癌(NSCLC):PROFILE 1001研究更新结果及总生存分析
本文报告I期PROFILE 1001研究更新结果(额外随访46.2个月),53例ROS1重排晚期NSCLC患者接受克唑替尼250 mg每日两次口服,客观缓解率72%(95%CI 58%至83%),中位无进展生存期19.3个月(95%CI 15.2至39.1),中位总生存期51.4个月(95%CI 29.3至未达到),未发现新的安全性信号。
要点
- 53例ROS1重排晚期NSCLC患者接受克唑替尼治疗,中位治疗持续22.4个月,客观缓解率72%(95%CI 58%至83%)。
- 中位无进展生存期19.3个月(95%CI 15.2至39.1),中位总生存期51.4个月(95%CI 29.3至未达到)。
- 治疗相关不良事件主要为1或2级,无≥4级治疗相关不良事件,长期治疗未报告新的安全性信号。
核心结论
- 这些发现为ROS1重排晚期NSCLC的总生存提供了新基准,并继续显示克唑替尼在该分子亚组中具有临床意义的获益和安全性。
研究设计与样本
- 正在进行的I期PROFILE 1001研究,ROS1状态通过FISH或逆转录聚合酶链反应确定。
- 53例ROS1重排晚期NSCLC患者接受克唑替尼起始剂量250 mg每日两次口服,本次报告额外随访46.2个月。
主要发现
- 中位治疗持续时间为22.4个月,数据截止时12例患者(23%)仍在治疗中。
- 客观缓解率为72%(95%CI 58%至83%),包括6例确认完全缓解和32例确认部分缓解,10例疾病稳定。
- 中位缓解持续时间24.7个月(95%CI 15.2至45.3),不同患者亚组间客观缓解率一致。
- 中位无进展生存期19.3个月(95%CI 15.2至39.1),中位随访62.6个月期间共26例死亡(49%)。
- 中位总生存期51.4个月(95%CI 29.3至未达到),12、24、36和48个月生存概率分别为79%、67%、53%和51%,总生存与特定ROS1融合伴侣之间未观察到相关性。
关键数值与推荐
- 治疗相关不良事件按CTCAE v3.0主要为1或2级,无≥4级治疗相关不良事件,无导致永久停药的治疗相关不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC). Here, we present updated antitumor activity, overall survival (OS) and safety data (additional 46.2 months follow-up) for patients with ROS1-rearranged advanced NSCLC from PROFILE 1001. PATIENTS AND METHODS: ROS1 status was determined by FISH or reverse transcriptase-polymerase chain reaction. All patients received crizotinib at a starting dose of 250 mg twice daily. RESULTS: Fifty-three patients received crizotinib, with a median duration of treatment of 22.4 months. At data cut-off, treatment was ongoing in 12 patients (23%). The objective response rate (ORR) was 72% [95% confidence interval (CI), 58% to 83%], including six confirmed complete responses and 32 confirmed partial responses; 10 patients had stable disease. Responses were durable (median duration of response 24.7 months; 95% CI, 15.2-45.3). ORRs were consistent across different patient subgroups. Median progression-free survival was 19.3 months (95% CI, 15.2-39.1). A total of 26 deaths (49%) occurred (median follow-up period of 62.6 months), and of the remaining 27 patients (51%), 14 (26%) were in follow-up at data cut-off. Median OS was 51.4 months (95% CI, 29.3 to not reached) and survival probabilities at 12, 24, 36, and 48 months were 79%, 67%, 53%, and 51%, respectively. No correlation was observed between OS and specific ROS1 fusion partner. Treatment-related adverse events (TRAEs) were mainly grade 1 or 2, per CTCAE v3.0. There were no grade ≥4 TRAEs and no TRAEs associated with permanent discontinuation. No new safety signals were reported with long-term crizotinib treatment. CONCLUSIONS: These findings serve as a new benchmark for OS in ROS1-rearranged advanced NSCLC, and continue to show the clinically meaningful benefit and safety of crizotinib in this molecular subgroup. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier NCT00585195.
引用
- Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019. PMID: 30980071. doi:10.1093/annonc/mdz131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。